Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing - Diversity Supplement

西南部落国家的美洲印第安人参与癌症基因组测序 - Diversity Supplement

• 批准号: 10584299
• 负责人: JEFFREY M. TRENT
• 金额: $ 14.5万
• 依托单位: UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-02 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10584299
• 关键词: Address; Affect; Age; American Indians; Cancer Patient; Communities; Data Set; Databases; Death Rate; Diagnosis; Disease Outcome; Ethnic group; Genes; Genetic Research; Genetic Transcription; Genomics; Goals; Hispanic; Incidence; Malignant Neoplasms; Molecular; Mutation; Not Hispanic or Latino; Outcome; Pathogenesis; Pathway interactions; Population; Precision Medicine Initiative; Race; Renal Cell Carcinoma; Research; Sampling; Techniques; Translating; United States; cancer genome; cancer type; driver mutation; genome sequencing; health disparity; improved; insight; personalized medicine; precision medicine; targeted treatment; transcriptome sequencing; tribal Nation; tumor

Project Summary Cancer incidence and associated death rates affecting American Indian (AI) communities are significantly higher than other races in the United States. More specifically, renal cell carcinoma (RCC) is the most common form of cancer in AI populations with diagnoses occurring at a younger age when compared to other races. Current sequencing datasets that are used for improving personalized medicine lacks information from AI cancer samples due to the lack of AI involvement in genomic and genetic research. Our ultimate goal for this project is to translate our findings to improve precision medicine for all populations, understanding the unique causes and driver mutations in AI cancer patients is a necessity. We hypothesize that functionally relevant and unique mutational signatures and molecular pathway disruption exist in the AI cancer samples and their identification will provide significant insights into cancer pathogenesis, progression, and will also help to improve diagnoses and treatment. To address this hypothesis, we propose the following aims; 1). compare mutational signatures identified in renal cell carcinoma (RCC) in AI to Hispanic and non-Hispanic White tumor samples, and 2). determine transcriptional pathway disruption in AI RCC and compare to Hispanic and non- Hispanic White using RNA sequencing techniques. This project will be crucial in bridging the gap between precision medicine and AI cancer outcomes by identifying disrupted genes and molecular pathways and will help to identify targets for therapeutic management and improving the disease outcome in these communities thereby reducing RCC health disparities.

项目摘要 影响美洲印第安人（AI）社区的癌症发病率和相关的死亡率显着 高于美国其他种族。更具体地说，肾细胞癌（RCC）是最大的 与其他人相比 种族。用于改善个性化医学的当前测序数据集缺乏信息 AI癌症由于缺乏AI参与基因组和遗传研究而样本。我们的最终目标 该项目是为了翻译我们的发现，以改善所有人群的精确医学，了解 AI癌症患者的独特原因和驱动因素是必要的。我们在功能上假设这一点 AI癌样品中存在相关和独特的突变特征和分子途径破坏 他们的鉴定将为癌症发病机理，进展提供重大见解，也将 帮助改善诊断和治疗。为了解决这一假设，我们提出了以下目标； 1）。 比较AI中肾细胞癌（RCC）中鉴定出的突变特征与西班牙裔和非西班牙裔 白色肿瘤样品和2）。确定AI RCC中的转录途径破坏并进行比较 使用RNA测序技术的西班牙裔和非西班牙裔白色。该项目对于桥接至关重要 精确药物与AI癌症结果之间的差距通过鉴定基因和分子的差异 途径，将有助于确定治疗管理的目标并改善疾病结果 这些社区从而降低了RCC的健康差异。